Aurobindo Pharma Ltd Q3 FY18-19 Financial Results


    Key Highlights of Q3FY19 consolidated financials
    •Revenue from Operations at INR 5,269.7 Cr, witnessed a strong growth of 21.5% over corresponding previous period
    •US formulation sales of INR 2,433.2 Cr vs INR 1,909.6 Cr in Q3FY18, registering a robust growth of 27.4% YoY
    •Europe formulation sales at INR 1,292.8 Cr, an increase of 10.3% against Q3 last year
    • Growth Markets posted a strong growth of 36.1% YoY to INR 340.5 Cr
    • ARV sales at INR 281.3 Cr vs. INR 238.9 Cr, an increase of 17.8% over corresponding previous period
    •API sales witnessed a healthy growth of 20.4% YoY to INR 921.7 Cr
    • EBIDTA before Forex and Other income at INR 1,086.4 Cr vs INR 1,025.6 Cr in Q3 last year, grew by 5.9% ; EBITDA margin for the quarter was at 20.6%
    •Net Profit after JV share, minority interest at INR 712.2 Cr as against INR 595.0 Cr in the corresponding previous period, witnessing a growth of 19.7% YoY.
    •Basic & Diluted EPS is INR 12.15 per share.
    •Board has approved second interim dividend @ 125% i.e., INR 1.25 per equity share of INR 1/- for the year FY18-19
    •Research & Development (R&D) spend at INR 254.6 Cr, 4.8% of revenues
    •Received final approval for 14 ANDAs and tentative approval for 1 ANDA from USFDA


    Please enter your comment!
    Please enter your name here